Dr. Gamzu is acting head of clinical trials of NeuroHealing Pharmaceuticals. Dr. Gamzu received his doctorate in psychology from the University of Pennsylvania and his interests have focused on the discovery and testing of drugs in neurological diseases.  He is very experienced in the requirements, design and execution of clinical trials.  Dr. Gamzu has worked in the biopharmaceutical industry since 1971, in discovery with Hoffmann LaRoche, in clinical management and drug development with Warner-Lambert, where as VP drug development he had responsibility for the development of Cognex, the first drug approved for Alzheimer's, and Neurontin. Dr. Gamzu has served as CEO of Cambridge Neuroscience, and interim VP of development project leadership for Millennium Pharmaceuticals.  He has 100 publications in the area of neurology and psychopharmacology, including clinical studies in Parkinson’s, Alzheimer’s, traumatic brain injury and stroke.  Dr. Gamzu serves as scientific reviewer for several scientific and medical journals and has been on the editorial board of numerous neuroscience journals.